Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Adam Asch
The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Purpose of the Study: ME-401, a potent and selective oral PI3k inhibitor, is being evaluated in a Phase 1b study in patients (pts) with R/R B-cell malignancies (NCT02914938). 101 pts were...
Jamie Wood ;
Adam Asch ;
Igor Gorbatchevsky ;
John Pagel ;
Andrew Zelenetz ;
Nishitha Reddy ;
Deepa Jagadeesh ;
Anastasios Stathis ;
Huda Salman ;
Jacob Soumerai ;
Vaishalee Kenkre ;
Haresh Jhangiani ;
Judith Llorin-Sangalang ;
10/22/2019
Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results
Introduction:
Deepa Jeyakumar ;
Eunice S. Wang ;
Mark P. Chao ;
Ian W. Flinn ;
Indu Lal ;
Joshua F. Zeidner ;
David A. Sallman ;
Daniel A. Pollyea , MD, MS;
Guillermo Garcia-Manero , MD;
Naval G. Daver ;
Carol O'Hear ;
Paresh Vyas ;
Joseph G. Jurcic ;
Suman N. Kambhampati ;
Lin Gu ;
Monzr M. Al Malki ;
Anderson Tan ;
Adam Asch ;
Tiffany N. Tanaka ;
Terrence J. Bradley ;
11/04/2022
Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia: Phase 1b Results
Introduction:
Paresh Vyas ;
Joshua F. Zeidner ;
Suman N. Kambhampati ;
David A. Sallman ;
Monzr M. Al Malki ;
Richard Larson ;
Adam Asch ;
Gabriel Mannis ;
Wanxing Chai-Ho ;
Tiffany N. Tanaka ;
Terrence J. Bradley ;
Deepa Jeyakumar ;
Eunice S. Wang ;
Guan Xing ;
Mark P. Chao ;
Giri Ramsingh ;
Camille Renard ;
Naval G. Daver ;
Indu Lal ;
11/04/2022
Featured Webinar
Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications
Upcoming Events
February 2 – February 5
February 27 – March 1
March 17 – March 19
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
April 30 – May 5
May 1 – May 3
May 19 – May 21
See Full Calendar